Grafco Silver Nitrate (75% Silver Nitrate, 25% Potassium Nitrate) 12.74 mg; 38.21 mg Stick, 100-count — NDC 51662-1611-1 (Billing 51662-1611-01)
This is a package of 100 sticks of Grafco Silver Nitrate (75% Silver Nitrate, 25% Potassium Nitrate) 12.74 mg; 38.21 mg Stick from HF Acquisition Co LLC, DBA HealthFirst, marketed since Aug 2022 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 51662-1611-1 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 51662 labeler · 1611 product · 1 package
- Package marketed since
- Aug 10, 2022
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 5166216111 1
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 1117536
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Grafco Silver Nitrate is a topical stick containing silver nitrate and potassium nitrate. Silver nitrate is commonly used in topical form to cauterize or remove certain skin growths and lesions, while potassium nitrate functions as a supporting component in the formulation. This product is an unapproved drug marketed without a current FDA application, and it is available by prescription only.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 5, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 51662-1611-01 You're viewing this Main listing | 100 STICK in 1 TUBE | 2022-08-10 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Styptstix 38.21 mg/1; 12.74 mg 00404-1000-01 | Henry | 12 tubes | — | — | FDA listed | — |
| Grafco Applicator 15 Cm 38.21 mg/1; 12.74 mg 12165-0100-01 | GF | 100 sticks | — | — | FDA listed | — |
| Grafco Applicator 30 Cm 52.451 mg/1; 17.486 mg 12165-0200-03 | GF | 100 sticks | — | — | FDA listed | — |
| Grafco Applicator 45 Cm 73.4314 mg/1; 24.4804 mg 12165-0300-01 | GF | 1 stick | — | — | FDA listed | — |
| Silver Nitrate Applicators 25 mg/100mg; 75 mg/100mg 12870-0001-01 | Arzol | 10 packets | — | — | FDA listed | — |
| Grafco Silver Nitrate (75% Silver Nitrate, 25% Potassium Nitrate) 12.74 mg/1; 38.21 mgthis 51662-1611-01 | HF | 100 sticks | — | — | FDA listed | — |
| Avoca Flexible Caustic Applicator 30 mg/40mg 65875-0101-09 | Bray | 10 vials | — | — | FDA listed | — |
| Swabs 25 g/100mL; 75 g/100mL 68599-6303-08 | McKesson | 10 swabs | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
0.036 mg
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
0.0153 mg
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 5, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from HF Acquisition Co LLC, DBA HealthFirst labeler code 51662
- 0.5% LIDOCAINE HCl 5 mg/mL Injection, Solution NDC 51662-1600-3
- GLYCOPYRROLATE .2 mg/mL Injection NDC 51662-1601-1
- LABETALOL HCl 5 mg/mL Injection NDC 51662-1602-1
- XYLOCAINE- MPF (LIDOCAINE HCl ) 20 mg/mL Injection, Solution NDC 51662-1604-3
- 0.25% BUPIVACAINE HCl 2.5 mg/mL Injection, Solution NDC 51662-1606-3
- 0.9% SODIUM CHLORIDE 9 g/1000mL Injection, Solution NDC 51662-1609-1
- ATROPINE SULFATE .4 mg/mL Injection NDC 51662-1619-1
- NALOXONE HCl 4 mg/.1mL Spray NDC 51662-1620-1
- XYLOCAINE .01 mg/mL; 10 mg/mL Injection, Solution NDC 51662-1622-3
- VASOPRESSIN 20 [USP'U]/mL Injection NDC 51662-1623-1
- ATROPINE SULFATE 1 mg/mL Injection, Solution NDC 51662-1626-3
- Atropine sulfate .4 mg/mL Injection, Solution NDC 51662-1627-3
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE INDICATIONS: For cauterization of skin or mucous membrane and for removing warts and granulated tissue.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION Moisten the applicator tip with distilled, deionized or purified water and apply the silver nitrate to the affected area by holding, rubbing, or rotating the tip along the affected tissue. The strength of the action is controlled by the dilution with distilled, deionized or purified water. One silver nitrate applicator is generally sufficient for each application.
The action of the silver nitrate can be stopped by washing the area with saline solution (0.9% sodium chloride). Using saline solution to wet the applicator tips, or residual saline from wound flushing/washing will interfere with the action of silver nitrate resulting in cauterization failure. Only use distilled, deionized or purified water to wet applicator tips.
Blot dry wounds that have been flushed/washed with saline prior to applying silver nitrate.
⛔ Contraindications ▾
CONTRAINDICATIONS Silver salts stain tissue black due to deposition of reduced silver. The stain gradually disappears within a period of two weeks. Prolonged ingestion or absorption of silver compounds leads to deposition of silver in connective tissues, producing a slate-blue discoloration of the skin known as argyria. This discoloration may also appear on mucous membranes such as the margins of gums. The sclera of the eye is also stained.
⚠️ Warnings and Cautions ▾
WARNINGS & PRECAUTIONS WARNING: KEEP OUT OF REACH OF CHILDREN. The active ingredients are poisonous and may be fatal when ingested in sufficient doses. The symptoms include toxic gastroenteritis, which may lead to coma, convulsion, paralysis and profound alteration of respiration.
If poisoning occurs, immediately consult a physician. WARNING: DO NOT USE ON THE EYES. In case of eye contact, hold eyes open and immediately flush thoroughly with water for at least 15 minutes and consult a physician.
CAUTION: SILVER NITRATE IS A CAUSTIC SUBSTANCE. Chemical burns may result from inappropriate use of product. • Wear chemical resistant gloves while using this product. Wear other appropriate personal protective equipment as needed. • Take care to confine the silver nitrate to the area being treated by using an appropriate physical or chemical barrier to prevent staining or burning of untreated tissue. • Skin contact time with applicators should be minimal when used on thin delicate skin or neonates. • Avoid prolonged contact with skin or other surfaces since staining may occur.
CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED NDC 51662-1611-1 GRAFCO SILVER NITRATE 6" APPLICATORS (75% SILVER NITRATE, 25% POTASSIUM NITRATE) 100 PER TUBE HF Acquisition Co LLC, DBA HealthFirst 11629 49th Pl W. Mukilteo, WA 98275
📦 Storage and Handling ▾
STORAGE Store in the closed package at room temperature in a dry place protected from light. Silver nitrate will oxidize and turn dark brown upon exposure to light, however this does not affect the product’s potency or utility. Exposure to moisture can cause the tip to break or loosen from the applicator. Store away from vaporous chemicals.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - NDC 51662-1611-1 51662-1611-1 Serialized Tube Labeling Tube Labeling Serialized Label RFID Label Tube Label
About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |